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Abstract
Background: The PORPUS-P is a short questionnaire for measuring prostate-specific quality of life (QoL), which was
designed in Canada for use in prostate cancer (PC) patients. We aimed to generate a German version and compare
PORPUS-P scores of German reference men from the general population, and German and Canadian patients with newly
diagnosed PC who were scheduled to receive radical prostatectomy (RP) or radiotherapy (RT).
Methods: The study sample consisted of 988 reference men, 121 German and 66 Canadian PC patients scheduled for
RT, and 371 German and 68 Canadian PC patients scheduled for RP. All men completed the PORPUS-P (German postal
questionnaire, Canada personal interview). Data were gathered from PC patients before the start of therapy.
Results: Canadian patients were better educated than the German patients, and fewer were retired. Patients scheduled
to receive RT were older and more were retired. German RT patients had lower D'Amico risk scores and pre-treatment
Gleason scores than RP patients, and Canadian RT patients had higher pre-treatment PSA than RP patients. Urinary and
sexual dysfunction were seen in PC patients (especially RT patients), but were also common in the German reference
men. Crude mean PORPUS-P scores differed statistically significant between German RT and RP and Canadian RP and
RT patients, with RT patients having higher QoL scores. The differences in age-adjusted mean PORPUS-P scores between
reference men and RP patients were not clinically significant, while RT patients had (clinically) significantly lower scores
than the reference men.
Conclusion: The German translation of the PORPUS-P appears to be a short and feasible tool for assessing prostate-
specific QoL. Although we found a similar response pattern, Canadian and German PC patients scheduled to receive RT
or RP rated their pre-treatment quality of life on different levels, which reveals the need for national reference data.
Problems in several QoL domains exist before treatment, and differ between PC patients scheduled for RT and RP.
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Background
Prostate cancer (PC) is one of the leading malignancies
worldwide, with 543,000 new cases each year [1]. In Ger-
many, tumours of the prostate gland account for about
25% of all malignant diseases (i.e. 58,000 incident cases
each year) [2]. It is estimated that in 2008, 24,700 men in
Canada were diagnosed with PC (28.4% of all neoplasms
in males). Today, 5-year survival rate is > 80% (compared
with ~60% in 1970). The increase is mainly due to system-
atic use of PSA screening and optimized therapy regimens
[2,3]. Depending on age and extent of disease different
modes of therapies can be used. Patients aged 75 years or
more are often not eligible for radiotherapy (RT) or radi-
cal prostatectomy (RP), but are treated with androgen
deprivation therapy (ADT). In patients with a life expect-
ancy of more than 10 years curative treatment is intended
[4]. D'Amico low risk patients [5] can choose between RP
and RT (either external beam (EB), seed implantation
(BRT) without removal of seeds, or a combination of both
of EB and BRT) [4].
However, radiation is frequently used – especially in
patients with intermediate or high D'Amico risk score,
and a high degree of co-morbidity. Both therapies have a
similar impact on survival, but a different impact on qual-
ity of life (QoL). The most common late complications of
radical prostatectomy are erectile dysfunction (ED;
defined as the persistent inability to achieve or maintain
an erection sufficient for satisfactory sexual performance
[6]), urinary incontinence, inguinal hernia, and urethral
stricture. The main adverse side effects of radiation ther-
apy are related to injury to the microvasculature of the
bladder, rectum, striated sphincter muscle, and urethra.
Approximately half of patients develop ED after radiother-
apy for prostate cancer [2]. After radical prostatectomy the
long-term impotence rate is approximately 40–75% [7].
Many of these symptoms are also found in the general
population. In the United States more than 30 million
men have ED and in Germany the age-adjusted ED preva-
lence rates are estimated to be between 18 and 48% [8]. A
2003 survey of 4,539 Canadian men aged 40 years and
older and involved in a heterosexual relationship found
that 34% of respondents had ED [9]. Moreover, a study in
2,498 participants demonstrated that urinary inconti-
nence is also frequent in the general population. Overall,
26.3% of women and 5.0% of men reported episodes of
urinary incontinence during the past 4 weeks. Prevalence
rates increased with age in both sexes [10].
Both ED and urinary incontinence influence activities of
daily life, social life, role function, and overall QoL. In the
study of Temml and colleagues 65.7% of women and
58.3% of men stated that their QoL was affected by their
incontinence [10]. This illustrates the need for QoL instru-
ments that include sexual, urinary and bowel dysfunction.
This is particularly important in assessing QoL in PC
patients. Unlike most generic QoL questionnaires, the
Patient Oriented Prostate Utility Scale (PORPUS) takes
the above mentioned key determinants of QoL into
account. The PORPUS was designed to be a utility instru-
ment (PORPUS-U), but it can also be used as a psycho-
metric instrument (PORPUS-P) [11,12].
In this paper we present the German version of the POR-
PUS-P and data from three different groups: a German ref-
erence population, German patients with newly-
diagnosed PC, and Canadian patients with newly-diag-
nosed PC.
Methods
San BKK-study (Reference data for German males)
A population-based sample of 3,000 men was randomly
selected from the computer records of a German statutory
health insurance company (Sancura BKK). No medical
exclusion or inclusion criteria were defined, as we
intended to investigate health-related QoL in the general
population. The only exclusion criterion was an age less
than 45 or greater than 75 years [13]. First, an introduc-
tory letter was sent to the men, describing the study and
its aims (i.e. measuring prostate-specific QoL in the gen-
eral population). After 14 days the study questionnaire,
which included questions on sociodemographics and
QoL (PORPUS [11,12] and other QoL measures), was
mailed with a pre-stamped return envelope. The mailing
was conducted during March and April 2004. During this
time period Sancura BKK personnel were available by tel-
ephone in case of questions about the questionnaires.
All 1,150 males who returned their completed question-
naire within four weeks were in our reference sample of
German males.
We followed a strict anonymization protocol by which
study identification numbers were kept separate from per-
sonal data such as name and address. In order to provide
a high level of anonymity, the mailing was carried out by
a neutral private company. Flagging of questionnaires
with an identification number was not allowed for data
protection reasons. Furthermore, completed question-
naires had to be sent directly to the study centre and not
to the neutral private company. Therefore a non-
responder analysis was not possible for the San BKK-
study.
The ProCaSP study (German men with newly diagnosed 
prostate cancer)
Data from men with newly-diagnosed PC were obtained
within the prospective cohort study ProCaSP. In ten Ger-
man hospitals 529 patients with PC were recruited, ofBMC Cancer 2009, 9:295 http://www.biomedcentral.com/1471-2407/9/295
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which 395 were scheduled to have a radical prostatectomy
(RP) and 134 were scheduled for radiotherapy (RT)
(recruitment period: April 2002 to October 2006).
Exclusion criteria were an age greater than 75 years, the
presence of metastasis and/or other primary tumours, a
psychiatric diagnosis recorded on the clinic chart, and a
history of cognitive impairment. Furthermore, patients
were excluded if they were not fluent in German.
All patients received a clinical examination, were asked for
co-morbidities and personal case history (information
was documented on a standardized case report form) and
completed self-administered questionnaires regarding
sociodemographic data and QoL (amongst others: POR-
PUS [11,12]) before they received RT or RP. During the
clinic visits trained, skilled personnel were available in
case of questions about the questionnaires; afterwards a
telephone hotline was implemented.
Data from the clinical investigation (pre-treatment PSA,
biopsy Gleason score and clinical stage) were used to
compute the D'Amico risk score [5], which is used to esti-
mate the biologic aggressiveness of prostate cancers and to
estimate the progression-free survival.
Canadian Study
Patients diagnosed with clinically localized PC within the
previous six months were recruited from ambulatory care
clinics of urologists and radiation oncologists at the Prin-
cess Margaret Hospital, a regional cancer centre and hos-
pital associated with the University Health Network in
Toronto, Canada. Patients were scheduled to receive RP,
or external beam radiation therapy or brachytherapy (RT),
with or without neo-adjuvant androgen deprivation ther-
apy, for the first time. Patients were excluded if they were
not fluent in English, had a documented history of cogni-
tive impairment, or had a psychiatric diagnosis recorded
on the clinic chart.
Consenting patients completed the PORPUS and other
QoL measures at a personal interview. Demographic and
clinical information was collected by self-report and chart
review, and included age, marital status, employment, liv-
ing arrangements, the three most recent PSA levels,
tumour stage, androgen deprivation therapy, and co-mor-
bid diseases required to calculate Charlson co-morbidity
scores [14].
Ethics and consent
The German study protocols were approved by the ethics
committee of the Giessen university hospital, Germany.
The Canadian study protocol was approved by the ethics
review committee of the University Health Network,
Toronto.
All persons participated voluntarily and gave written
informed consent.
PORPUS
The PORPUS [11] is a 10-item health state classification
system. Each item describes a QoL domain that is relevant
to PC. These domains were identified through an iterative
process involving interviews with patients and clinical
experts, and include five broad QoL domains (pain,
energy, emotional well-being, social support, relationship
with medical doctor) and five PC-specific domains (sex-
ual function and desire, urinary frequency and inconti-
nence, bowel function). Within each domain or item,
there are four to six text descriptions representing a range
of symptom severity. For example, for urinary leakage, the
worst level is "Require a clamp, catheter, or collecting bag
because of leaking urine or poor bladder control" and the
best level is "Never, under any circumstances, leak urine
or lose bladder control".
The PORPUS may be used as a profile, disease-specific,
non-preference based instrument to compute a QoL
measure that we call the PORPUS-P [11,12]. The PORPUS
can also aid in direct utility assessment when it is admin-
istered by a trained interviewer using a script (available on
request), 4 marker states, and visual props for Rating Scale
and Standard Gamble elicitation [11]. Patients first
describe their current health by selecting one level from
each attribute of the PORPUS-P. This health state descrip-
tion is placed on a colour-coded card and patients rank it,
and 4 marker states (mild impairment, severe impair-
ment, full health, and death), in order of preference.
Patients' utilities for their own health state, and the mild
and severe impairment marker states, are obtained using
the Rating Scale (PORPUS-URS) and Standard Gamble
(PORPUS-USG), following the script. This prompted
method of utility assessment has face, content, and con-
struct validity, and good test-retest reliability
[11,12,15,16], but it is time-consuming and requires a
trained interviewer and visual props. Recently, utility
weights for PORPUS health states were developed, using
direct utility assessment in 234 prostate cancer patients in
Canada and a multi-attribute utility function [Tomlinson
G, Bremner K, Ritvo P, Naglie G, Krahn M: Development
and validation of a utility weighting function for the POR-
PUS – Patient Oriented Prostate Utility Scale, submitted].
Thus, the PORPUS can also be used as an indirect, disease-
specific utility instrument.
German Version of the PORPUS
Following the EORTC guidelines for translation proce-
dures [17], we used the forward-backward-translation
method to generate the German version of the original
English-Canadian PORPUS questionnaire [11,12,18]. The
translation process began with forward translation into
German conducted by a German native speaker with aBMC Cancer 2009, 9:295 http://www.biomedcentral.com/1471-2407/9/295
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high level of fluency in English. Backward translation was
conducted independently of the first translator by a Cana-
dian who was fluent in German. This process was repeated
until a satisfactory translation was obtained.
The item ''Emotional well-being" is a 5-point item in the
original Canadian PORPUS-P. Because there is no ade-
quate German translation of "quite a bit" in contrast to
"moderate" and "little" the German version of this item
was constructed as a 4-point item (see additional file 1).
Therefore, we were unable to score the PORPUS as an util-
ity instrument.
Scoring procedure
According to the scoring manual the scores for each item
range from 0 to 3 (in case of 4 point scales), 4 or 5 (5 or 6
point scales respectively) with high values indicating a
high level of deterioration or symptomatology. After res-
caling the data so that the range within each item is equiv-
alent (i.e. dividing each item by the number of possible
answer categories) all values are summed and multiplied
by 10 and by the number of required responses divided by
the number of completed items. The resulting value has to
be subtracted from 100 to calculate the PORPUS-P-score
(see Formula 1).
The resulting PORPUS-P-score ranges from 0 to 100 with
high values indicating high QoL. At least 8 out of 10 items
have to be completed for a PORPUS-P score to be com-
puted.
N1 is the number of responses required (i.e., 10)
N2 is the number of non-missing responses
S are the non-missing responses
Formula 1: Equation for computing PORPUS-P scores
Statistical methods
SPSS 15.0 (SPSS version 15.0 for Windows, SPSS Inc. Chi-
cago, Illinois, USA; 1989–2006) was used to analyse the
German data.
SAS version 9.1 (SAS 9.1 for Windows, SAS Inc. Cary,
N.C., USA; 2002–2003) was used for all analyses of the
Canadian data.
We used descriptive statistics (means, standard deviations
(SD), median and 5th and 95th percentiles), analysis of var-
iance, and chi-square tests to describe and compare the
baseline characteristics of the two patient groups (RP, RT)
within each country. Distribution of PORPUS-P scores
was checked visually (histograms) and using Kol-
mogorov-Smirnov tests.
Spearman correlation coefficient is reported for the asso-
ciation between age categories and PORPUS-P scores. For
interpretation of correlation coefficients the following
ranges were chosen: correlation coefficients ranging from
zero to 0.2 were considered as indicating a very low asso-
ciation, 0.2 to 0.5 = low association, 0.5 to 0.7 = moderate
association, greater than 0.7 = high association. Two-sided
p-values ≤ 0.05 were considered significant.
In order to check whether the fact that there were missing
values in the German studies but not in the Canadian
study biased the PORPUS-P results or not, best-case and
worst-case analyses were performed. For this purpose
missing values were replaced with either the value indicat-
ing the level with no problems (i.e. "zero"), or the value
indicating the level with the most severe problems
(depending on the PORPUS-item; score "three", "four", or
"five"), respectively.
Indirect age-standardization was used to generate age-
adjusted means for the PC patients (reference age struc-
ture = age structure in German reference males). During
this process the age distributions of the different sub-
groups (German and Canadian RT and RP patients) are
standardized to the age structure observed in German ref-
erence males. Because young German patients scheduled
to receive radiotherapy were not present in the data set,
the age-group 45 to 49 years had to be excluded for the
indirect age-standardization.
The resulting adjusted mean is the mean that would have
been observed if the patient groups would have had the
same age structure as the reference men.
Results
Study cohort 1: German reference males
Due to missing or implausible information on age (n =
16), education (n = 20), working status (n = 2), marital
status (n = 6), or one of the items needed to compute
scores on the QoL instruments (PORPUS-P or other QoL
instruments that were included in the questionnaire; n =
125), 162 males had to be excluded from the analysis. The
total sample consisted of 988 men from the German gen-
eral population. Baseline data is shown in Tables 1, 2, 3, 4.
The 162 excluded men (with valid data) were – compared
to men of our reference sample – a little older (mean age:
58.5 ± 8.1 years; p < 0.001), more likely to be retired
(48.7%; p < 0.001), less educated (< = 9 years schooling:
69.7%; p = 0.053), and reported lower health related
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quality of life on the PORPUS-P (crude mean and stand-
ard deviation: 78.5 ± 15.6 vs. 83.5 ± 12.1; p < 0.001).
Study cohort 2: German Patients with prostate cancer
In total, 529 patients with newly-diagnosed PC were
recruited and completed a baseline questionnaire. A sub-
sample of 496 provided valid data to compute baseline
PORPUS-P (33 had more than two missing answers, thus
no PORPUS-P score could be computed). A further four
patients were excluded from the final analysis due to miss-
ing sociodemographic (n = 2) or clinical data (Gleason
score; n = 2). Therefore, our final cohort consisted of 492
men with PC with complete baseline questionnaires, of
whom 121 were scheduled to receive RT and 371 were
scheduled to receive radical prostatectomy. Systematic dif-
ferences in age, sociodemographics, D'Amico risk scores,
and therapy between persons included in our analyses (n
= 492) and those who were excluded (n = 37) were not
observed (data not shown).
Among the 121 RT patients, 39 patients (32.2%) were
scheduled to receive BRT and 33 (27.3%) were scheduled
to receive a combination of EB and BRT. BRT patients did
not differ from the other RT patients in age (BRT: 65.7 ±
5.1 years, EB/BRT: 66.4 ± 5.4 years, EB: 67.6 ± 4.9 years; p
= 0.188) or pre-treatment PSA (BRT: 11.4 ± 15.8 ng/ml,
EB/BRT: 16.7 ± 13.3 ng/ml, EB: 13.5 ± 20.4 ng/ml; p =
0.440). However, patients with BRT or EB/BRT had lower
Gleason scores (BRT: 5.6 ± 1.1, EB/BRT: 6.2 ± 1.7, EB: 6.5
± 1.1; p = 0.01) and less frequent small tumours (BRT:
14.3% T1, EB/BRT: 3.6% T1, EB: 55.3% T1, p < 0.001).
Fewer patients scheduled to receive RP were on androgen
deprivation therapy (ADT; 1.9%) than RT patients
(40.5%, 49 cases). Of the latter, 12 were scheduled for EB/
BRT and 20 were scheduled for BRT.
Study cohort 3: Canadian patients with prostate cancer
A total of 305 newly-diagnosed PC patients were invited
to participate in the study, and 138 were interviewed. Four
had poor language skills and could not understand the
questionnaires so 134 completed the interview. Sixty-
eight (51%) were scheduled to have a RP, and 66 (49%)
were scheduled for RT, of whom 61 were scheduled to
receive EB, and 5 were scheduled for BRT (for baseline
description refer to Tables 1, 2, 3, 4). Among the RT
patients, the 5 patients who were scheduled to receive BRT
had significantly lower maximum pre-treatment PSA (4.3
± 2.7 ng/ml vs. 15.1 ± 14.9; p < 0.001), and were all stage
T1–T2, but were not significantly different in age (BRT:
65.8 ± 5.8 years, EB: 68.0 ± 6.3 years). In addition, 30 of
the RT patients (45%, including one BRT patient) had
started ADT by the time of the baseline interview, com-
pared to only 5 (7%) of the RP patients.
PORPUS-P
Table 5 shows the PORPUS-P scores for the German refer-
ence men and each treatment and age group of the Ger-
man and Canadian PC patients. PORPUS-P scores can
range from 0–100; in all subgroups mean scores were in
the upper quarter of the scale (indicating high QoL) with
the exception of Canadian RT patients aged 50–54 years
(n = 2). Means and medians of the subgroups are very
similar and indicate a slight right-sided distribution
(PORPUS-P scores of German and Canadian RT patients
were normally distributed, while data for RP patients was
not; Germany: p = 0.013; Canada: p = 0.028 in Kol-
mogorov-Smirnov tests). In both the German and Cana-
dian cohorts, PC patients about to receive RT had
significantly lower crude PORPUS-P scores than those
who were about to receive RP (in German data: p = 0.005,
in Canadian data: p = 0.001). The age-adjusted means dif-
fered slightly between German RT and RP patients and dif-
Table 1: Age distribution of the study samples (N; percentages in parentheses)
German 
reference men 
[n = 988]
German PC 
patients with 
scheduled 
radiotherapy 
[n = 121]
German PC 
patients with 
scheduled 
radical 
prostatectomy 
[n = 371]
p-values for 
differences 
between 
German RT and 
RP patients
Canadian PC 
patients with 
scheduled 
radiotherapy 
[n = 66]
Canadian PC 
patients with 
scheduled 
radical 
prostatectomy 
[n = 68]
p-values for 
differences 
between 
Canadian RT 
and RP patients
Age [years]
Mean ± SD
56 ± 7.6 67 ± 5.1 63 ± 6.2 p < 0.001* 68 ± 6.3 60 ± 6.3 p < 0.001*
Age category 
[years]
p < 0.001# p < 0.001#
45–49 253 (26) 0 (0) 13 (4) 1 (2) 1 (1)
50–54 239 (24) 2 (2) 31 (8) 2 (3) 14 (20)
55–59 162 (16) 10 (8) 57 (15) 4 (6) 18 (26)
60–64 166 (17) 26 (22) 117 (32) 9 (14) 17 (25)
65–69 127 (13) 43 (36) 115 (31) 21 (20) 11 (16)
70+ 41 (4) 40 (33) 38 (10) 29 (44) 7 (10)
* analysis of variance # chi-square testsBMC Cancer 2009, 9:295 http://www.biomedcentral.com/1471-2407/9/295
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fered in a clinically relevant way (difference of 10.3
points) between Canadian RT and RP patients.
ADT influenced (crude) PORPUS-P-scorings of all Cana-
dian patients (with ADT: 74.0 ± 10.4, without ADT: 84.4
± 10.4; p < 0.001), of all German patients (with ADT: 76.5
± 12.8, without ADT: 80.5 ± 12.4; p = 0.029), and of all
Canadian RT patients (with ADT: 72.5 ± 10.2, without
ADT: 82.5 ± 10.8, p < 0.001), but not of Canadian RP
patients, German RT and RP patients.
Furthermore, some very low to low but statistically signif-
icant inverse associations were observed between age and
PORPUS-P scores in the reference men (r = -0.232, p =
Table 2: Characteristics of the study samples (N; percentages in parentheses)
German 
reference men 
[n = 988]
German PC 
patients with 
scheduled 
radiotherapy 
[n = 121]
German PC 
patients with 
scheduled 
radical 
prostatectomy 
[n = 371]
p-values for 
differences 
between 
German RT and 
RP patients
Canadian PC 
patients with 
scheduled 
radiotherapy 
[n = 66]
Canadian PC 
patients with 
scheduled 
radical 
prostatectomy 
[n = 68]
p-values for 
differences 
between 
Canadian RT 
and RP patients
Education p = 0.980# p = 0.50#
high school or 
less 
(up to 11–12 
yrs)
768 (78) 84 (69) 258 (69) 23 (35) 20 (29)
college or 
university 
(12 yrs or 
more)
220 (22) 37 (31) 113 (31) 43 (65) 48 (71)
Part-/fulltime 
workers
588 (60) 16 (13) 135 (36) p =< 0.001# 22 (33) 47 (69) p < 0.001#
Married or 
common law
894 (91) 111 (92) 350 (94) p = 0.306# 59 (89) 54 (79) p = 0.112#
Living alone 73 (7) 9 (7) 22 (6) p = 0.548# 9 (9) 7 (10) p = 0.81#
# chi-square tests
Table 3: Clinical characteristics of the study samples (N; percentages in parentheses)
German 
reference men 
[n = 988]
German PC 
patients with 
scheduled 
radiotherapy 
[n = 121]
German PC 
patients with 
scheduled 
radical 
prostatectomy 
[n = 371]
p-values for 
differences 
between 
German RT and 
RP patients
Canadian PC 
patients with 
scheduled 
radiotherapy 
[n = 66]
Canadian PC 
patients with 
scheduled 
radical 
prostatectomy 
[n = 68]
p-values for 
differences 
between 
Canadian RT 
and RP patients
D'Amico Risk 
Score
Not p < 0.001#
Low 39 (32.2) 24 (6.5)
Intermediate 39 (32.2) 46 (12.4)
High applicable 43 (35.5) 301 (81.1) - -
Gleason score 
(pre-treatment)
Mean ± SD
Not applicable 6.13 ± 1.33 6.35 ± 1.21 p < 0.096* - -
Highest 
recorded pre-
treatment PSA 
[ng/ml] 
(mean ± SD)
Not applicable 13.7 ± 17.3 10.2 ± 17.9 p = 0.066* 14.3 ± 14.6 8.81 ± 6.9 p = 0.006*
Gleason score and D'Amico risk score were not assessed in the Canadian study
* analysis of variance # chi-square testsBMC Cancer 2009, 9:295 http://www.biomedcentral.com/1471-2407/9/295
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Table 4: Tumor stage at diagnosis of the study samples (N; percentages in parentheses)
German 
reference men 
[n = 988]
German PC 
patients with 
scheduled 
radiotherapy 
[n = 121]
German PC 
patients with 
scheduled 
radical 
prostatectomy 
[n = 371]
p-values for 
differences 
between 
German RT and 
RP patients
Canadian PC 
patients with 
scheduled 
radiotherapy 
[n = 66]
Canadian PC 
patients with 
scheduled 
radical 
prostatectomy 
[n = 68]
p-values for 
differences 
between 
Canadian RT 
and RP patients
Tumour stage 
at diagnosis
Not applicable p < 0.001# p = 0.008#
T1 28 (23.1) 2 (0.5) 18 (27) 21 (31)
T2 34 (28.1) 239 (64.4) 29 (44) 30 (44)
T3 20 (16.5) 122 (32.9) 14 (21) 1 (1.5)
T4 0 0 1 (1.5) 0
missing 39 (32.2) 8 (2.2) 4 (6) 16 (23.5)
# chi-square tests
Table 5: Scores of PORPUS-P by age categories and type of therapy to be received (Mean ± SD, Median, 5th and 95th percentiles)
German reference 
men [n = 988]
German PC 
patients with 
scheduled 
radiotherapy 
[n = 121]
German PC 
patients with 
scheduled radical 
prostatectomy 
[n = 371]
Canadian PC 
patients with 
scheduled 
radiotherapy 
[n = 66]
Canadian PC 
patients with 
scheduled radical 
prostatectomy 
[n = 68]
Age category [years]
45–49 n = 253 n = 13 n = 1 n = 1
87.0 ± 9.70 - 84.8 ± 8.80 83.0 84.2
88.3 (66.8/100) - 88.3 (66.8/97.5) - -
50–54 n = 239 n = 2 n = 31 n = 2 n = 14
85.2 ± 11.7 77.8 ± 8.61 82.3 ± 11.9 65.8 ± 13.0 92.1 ± 4.4
83.3 (61.7/100) 77.8 (71.7/83.8) 83.3 (58.2/100) 65.8 (56.7/75.0) 91.7 (85.8/100)
55–59 n = 162 n = 10 n = 57 n = 4 n = 18
83.1 ± 12.0 77.1 ± 16.2 81.3 ± 12.5 84.8 ± 5.1 86.5 ± 10.1
86.3 (62.2/97.5) 77.8 (42.7/100) 84.2 (57.4/95.2) 82.4 (82.2/92.5) 87.1 (69.2/100)
60–64 n = 166 n = 26 n = 117 n = 9 n = 17
80.9 ± 12.1 77.6 ± 12.7 82.0 ± 11.5 80.3 ± 17.4 85.5 ± 8.2
84.0 (57.2/97.5) 78.5 (53.9/98.3) 83.3 (59.2/98.2) 85.0 (46.3/100) 86.7 (71.3/97.5)
65–69 n = 127 n = 43 n = 115 n = 21 n = 11
79.5 ± 13.4 76.9 ± 12.5 79.8 ± 14.1 77.9 ± 10.7 78.5 ± 12.5
80.8 (57.4/97.5) 76.7 (52.8/94.8) 82.7 (52.3/98.0) 78.8 (65.3/95.0) 79.2 (55.8/95.0)
70+ n = 41 n = 40 n = 38 n = 29 n = 7
76.7 ± 15.5 77.2 ± 12.4 76.8 ± 10.7 77.0 ± 10.6 78.8 ± 9.1
78.8 (49.1/97.5) 80.4 (52.2/92.5) 77.8 (56.5/95.0) 75.0 (62.5/92.5) 77.5 (67.2/92.5)
Total (Crude values) 83.5 ± 12.1 77.2 ± 12.6 80.8 ± 12.4 78.0 ± 11.6 85.3 ± 9.9
86.1 (59.8/97.5) 79.2 (53.5/94.4) 83.0 (58.0/97.5) 78.8 (62.5/97.5) 87.5 (69.2/97.5)
Age-adjusted means 
(norm: ref. pop.; 50 and 
older)
82.3 77.4 81.3 76.0 86.3BMC Cancer 2009, 9:295 http://www.biomedcentral.com/1471-2407/9/295
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0.003), German patients (r = -0.133, p = 0.003) and Cana-
dian patients (r = -0.375, p < 0.001) and in the subgroups
of German and Canadian RP patients (r = -0.121, p =
0.019, and r = -0.413, p = 0.005) respectively, but not for
RT patients.
Figures 1, 2, 3 show the distribution of responses for the
reference men and PC patients (aged 55 years or more).
About 63% of the German patients, and 67% of the Cana-
dian patients reported problems related to urinary fre-
quency or urgency (level 2–5; Figure 2), 49% (German)
and 27.6% (Canadian) indicated moderate to low energy
(level 3–5), and 54.5% (German) and 44% (Canadian)
patients reported mild to severe pain (Figure 1). Bowel
problems were reported by 26.9% of the German patients
and 23% of the Canadians (Figure 3). Approximately 46%
of the reference men reported problems related to urinary
frequency or urgency (Figure 2). Energy was considered to
be moderate or low by 54.3%, mild to severe pain was
reported by 62.9% (Figure 1), and bowel problems were
present in 23% of the reference men (Figure 3).
In the German studies, up to two missing values were
allowed on the PORPUS. The Canadian study was con-
ducted by personal interview, so all patients answered all
PORPUS items. As shown in figure 2 in German men aged
55 years or more the items concerning sexual function
and sexual interest/drive had the highest proportions of
missing values (patients: 3.8% and 4.5%; reference popu-
lation: 1.8% and 2.4%).
Discussion
In this paper, we are reporting on pre-treatment prostate-
specific quality of life (QoL) in newly-diagnosed PC
patients with a maximum age of 79 years, who were
scheduled to receive either RT or RP and in German refer-
ence men from the general population.
Differences between German and Canadian study cohorts
As shown in Tables 1, 2, 3, 4, the German reference men
and newly-diagnosed PC patients from Germany and
Canada differ in some aspects. In the Canadian study
more men were still working than in Germany (Table 2) –
although Canadian cancer patients were a little older than
German patients (Table 1). In Germany, the usual retire-
ment age of men belonging to the birth cohort 1940 is 65
years. But early retirement, usually at 63 years of age, is
possible. In Canada, the usual age for retirement is also 65
years, but many retire as early as 60 years of age, while
professionals and self-employed people may work after
age 65, either full-time or part-time. Differences between
the study groups are also found regarding educational
attainment (Table 2). In Germany in 2007, 13% of people
over age 45 years had at least 10 years of schooling and
another 13% had 12 years [19]. In Canada in 2006, 25%
of persons aged 45 to 64 completed high school (12 years
of schooling), and 19% had a university degree [20].
Therefore, the Canadian patients in this study were better
educated than the Canadian population and than the Ger-
man cohorts.
From other studies it is known that besides co-morbidity,
education and employment affect QoL ratings [21,22].
Because of this and the fact that the two studies were not
originally designed for cross-national comparisons, we
did not perform statistical tests for differences between
QOL scorings of German and Canadian men.
Differences between patients scheduled to receive 
radiation therapy or radical prostatectomy
As shown, PC patients from Germany and Canada differ
in some aspects which may affect QoL. However, differ-
ences also were found between patients scheduled to
receive RP and RT (e.g. age (Table 1), education (Table 2),
and disease stage (Tables 3, 4)). Other studies, too,
reported that patients scheduled for RT (or who have
received RT) were older than patients scheduled for RP
[23,24], had higher pre-treatment PSA, higher Gleason
scores, and more progressed tumours as indicated by T-
stage [24,25]. There are two possible reasons for the
observed age differences. Older age may be regarded as a
risk factor for undesired side effects of surgical procedures,
thus RT may be recommended to older men. Secondly,
the EAU guideline states that one indication for surgery
(RP) is that the expected post-operative survival should be
10 years or more [4]. With increasing age and associated
co-morbidities expected survival decreases, therefore
older patients might be more likely to receive RT. Further-
more, tumours in younger patients are often more aggres-
sive, so an early excision of the tumour with surgery is
indicated.
Health related quality of life and prostate specific 
symptoms
We used a prostate-specific tool for assessing QoL: The
Patient Oriented Prostate Utility Scale (PORPUS, see addi-
tional file 1). This tool is unique in that takes key determi-
nants of QoL such as sexual, urinary and bowel
dysfunction into account [11]. Its acceptability, reliability,
and validity [11,12,15,16] make it a valuable tool not
only in study situations. Due to its shortness, the POR-
PUS-P can be easily integrated into daily routine in urol-
ogy practices. The paper-and-pencil form can be
completed in approximately 3:30 minutes (pilot study
with 20 German men; mean age: 48 years (SD: 15 years);
50% had less than 12 years schooling).
Originally, the PORPUS-P was designed for use in PC
patients. But its QoL domains are also relevant among
men in the general population, as with increasing ageBMC Cancer 2009, 9:295 http://www.biomedcentral.com/1471-2407/9/295
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Distribution of answers for the single items pain, energy, support, and communication (in %) Figure 1
Distribution of answers for the single items pain, energy, support, and communication (in %).
1. No pain and no disturbing body sensations. 
2. Mild pain or disturbing body sensations that do not 
limit any activities (for example: work, social, sexual, 
sleep).
3. Moderate pain or disturbing body sensations that 
limit a few activities. 
4. Moderate to severe pain or disturbing body 
sensations that limit some activities. 
5. Severe pain or disturbing body sensations that limit 
many activities.
1. Very full of energy, lots of pep. 
2. Fairly energetic, no limitation of activities (for 
example: work, social, sexual). 
3. Moderate reduction in energy or pep that limits a 
few activities. 
4. Generally low energy or pep that limits some 
activities. 
5. No energy or pep at all.  I feel drained, and many 
activities are limited.
1. Most of the time feel supported by my spouse, 
family and friends. 
2. A fair amount of the time feel supported by my 
spouse, family and friends. 
3. Occasionally feel supported by my spouse, family 
and friends. 
4. Rarely feel supported by my spouse, family, and 
friends. 
1. Always able to express my concerns to my Doctor 
and get all the information or advice I need. 
2. Most the time, able to express my concerns to my 
Doctor and get all the information or advice I need. 
3. Some of the time, able to express my concerns to 
my Doctor and get all the information or advice I 
need.
4. Rarely able to express my concerns to my Doctor 
and get all the information or advice I need. BMC Cancer 2009, 9:295 http://www.biomedcentral.com/1471-2407/9/295
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Distribution of answers for the single items emotional well-being, urinary frequency, urinary incontinence, and sexual function  (in %) Figure 2
Distribution of answers for the single items emotional well-being, urinary frequency, urinary incontinence, and 
sexual function (in %).
1. Generally happy and free from worry, sadness, or 
frustration. 
2. A little worry, sadness, or frustration.  
3. Moderate worry, sadness, or frustration. 
4. Quite a bit of worry, sadness, or frustration (missing 
in the German questionnaire)
5. Extreme worry, sadness, or frustration. 
1. No urinary frequency or urgency. 
2. A little urinary frequency or urgency, does not 
interfere with sleep or other activities (for example: 
work, social); no need to plan ahead. 
3. Some urinary frequency or urgency that interferes 
with sleep or other activities; may need to plan ahead. 
4. Quite a bit of urinary frequency or urgency; need to 
be near a bathroom most of the time. 
5. Extreme urinary frequency or urgency; need to be 
near a bathroom always. 
1. Never, under any circumstances leak urine or lose 
bladder control. 
2. On rare occasions, leak urine or lose bladder 
control, does not interfere with any activities (for 
example: work, social, sexual, sleep). 
3. Occasionally leak urine or lose bladder control, 
interferes with a few activities. 
4. A moderate amount of the time, leak urine or lose 
bladder control, interferes with some activities. 
5. Most of the time, leak urine or have poor bladder 
control, interferes with many activities. 
6. Require a clamp, catheter, or collecting bag because 
of leaking urine or poor bladder control. 
1. Full erections sufficient for intercourse. 
2. Erections sufficient for intercourse, but some 
reduction in firmness. 
3. Erections sufficient for masturbation or foreplay 
only. 
4. Erections, but not firm enough for any sexual 
activity. 
5. No erections at all. BMC Cancer 2009, 9:295 http://www.biomedcentral.com/1471-2407/9/295
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erectile dysfunction [8,9], urinary incontinence [10] and
bowel problems are common. Our study indicates that
approximately 20% of men in the general population and
of PC patients who have not yet been treated with RP or
RT, of all ages, have problems in these areas. These
observed prevalence rates are a little lower than reported
for the general population in Canada and Europe [8-10],
furthermore Staff et al. reported pre-treatment prevalence
rates for ED of 44% in US patients with localized PC, who
were scheduled to receive RT. However, impaired bowel
function (8%) or impaired urinary function (18%) was
less common in their study than in ours [26]. The authors
are only aware of one other study that used PORPUS-P in
non-metastatic PC patients and controls. In the study of
Joly et al. more PC patients on ADT reported low energy
(36%), poor bladder control (47%) and loss of sexual
function (95%) than age-matched controls (16%, 34%
and 33%, respectively), which could be attributed to the
cancer therapy [27].
Problems in other areas of QoL were also reported by our
respondents, notably energy level; only 9% of the appar-
ently healthy men, 13% of the German patients, and 26%
of the Canadian patients reported feeling "very full of
energy, lots of pep", while 6% of the German RT, 5% of
the German RP, 11% of the Canadian RT and 6% of the
Canadian RP patients reported having generally low
energy or pep (level 4) or having no energy at all (level 5).
Monga et al. showed that 8% of veterans (mean age: 67
years) with localized PC experienced fatigue before treat-
ment [28] and Joly et al. reported that 14% of non-metas-
tastic PC patients on ADT and 4% of controls experienced
severe fatigue [27]. Schwarz and Hinz assessed QoL with
the EORTC QLQ-C30 in the general German population.
Of all respondents 10% scored 50 or more points on the
fatigue scale (0–100, high scores indicate a high level of
symptomatology) [29].
The Canadian and the German version of PORPUS-P have
different response schemes for the item "emotional well
being". "Quite a bit of worry, sadness, or frustration" was
omitted from the German version, so respondents had
only 4 levels for this item (see Figure 2). Interestingly,
49.8% of the German patients but only 40% of the Cana-
dians reported being "generally happy and free from
Distribution of answers for the single items sexual interest and bowel problems (in %) Figure 3
Distribution of answers for the single items sexual interest and bowel problems (in %).
1. Normal amount of sexual drive and interest for you. 
2. A little decrease of sexual drive or interest for you. 
3. Moderate decrease of sexual drive or interest for 
you. 
4. Substantial decrease of sexual drive or interest for 
you. 
5. No sexual drive or interest. 
1. No diarrhoea, rectal discomfort, or constipation. 
2. Occasionally have diarrhoea, rectal discomfort, or 
constipation. 
3. Frequently have diarrhoea, rectal discomfort, or 
constipation 
4. Nearly always have diarrhoea, rectal discomfort, or 
constipation. BMC Cancer 2009, 9:295 http://www.biomedcentral.com/1471-2407/9/295
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worry, sadness, or frustration" (answer category 1). Con-
versely, only 9.3% of the German patients reported mod-
erate or extreme worry, sadness, or frustration (level 3 and
5), compared with 23% of the Canadian patients who
reported moderate, quite a bit, or extreme worry, sadness,
or frustration (level 3–5). We do not think that the
observed differences are only due to the different response
formats in the Canadian and the German versions of the
PORPUS. It is possible that "emotional well being" is a
different concept in the studied countries.
Comparing the response patterns in Germany and Can-
ada (Figures 1, 2, 3), there are differences between the
Canadian English version, as used in Canadian PC
patients, and the German version as used in German men
(i.e. emotional well being, sexual function), but many of
the answer distributions are similar.
The crude PORPUS-P scores differ significantly between
RT and RP patients from Germany (mean scores: 77 vs.
81) and Canada (mean scores: 78 vs. 85), respectively.
Focusing on the age-specific strata it appears that, in refer-
ence men, mean scores decrease by about 4 points per 10
years. Also Schwarz and Hinz found detriments in QoL in
the general German population as age increased [29]. In
German RP patients, mean PORPUS-P scores decrease
after age 60. In Canadian RP patients, mean scores
decrease by at least 5 points every 10 years, and these
patients have the highest mean scores of all 5 groups up to
age 64. There is little or no evidence of age-related
decreases in the German or Canadian RT patients.
Based on the works of King et al. [30], Osoba et al. [31],
and Ringash et al. [32] a difference of five percent of the
scale range can indicate a minimal important difference
(i.e. clinically relevant difference). Since the PORPUS-P
has a 0 to 100 point scale, we assume a difference of 5
points is clinically relevant (but further studies have to
validate this assumption). Thus, we see clinically relevant
different PORPUS-P scores between German reference
men and German RT patients as well as clinically relevant
differences between the PORPUS-P scores of RT and RP
patients in both countries. Radiotherapy is often given to
PC patients with a higher degree of co-morbidity, which
might influence QoL ratings more than the (still
untreated) tumour. Other studies showed also that RT
patients rate their pre-treatment health related QoL lower
than RP patients – this effect is more pronounced when
disease specific QoL instruments are used than when
using generic instruments [25,33,34].
In our studies rates of ADT were quite similar for Cana-
dian and German RT patients (54 vs. 40%) and RP (2 vs.
7%) patients. Hormone therapy is also known to influ-
ence QoL [27] and (as expected) PORPUS-P scorings of all
Canadian and of all German patients differed significantly
between men with and without ADT. In accordance with
our results, Joly et al. [27] showed that non-metastatic PC
patients with at least three months of ADT had signifi-
cantly lower PORPUS-P scores than healthy age-matched
control men (median: 71 vs. 86; p < 0.001).
Missing values
The Canadian data, collected in personal interviews, have
no missing data, but the German studies were conducted
by mail so there were missing values. It is often assumed
that persons are unwilling to answer questions about sex-
ual and urinary function. This assumption is true for our
data; 18.1% of the German PC patients had missing data
for the item sexual function, 8.7% gave no answer to the
item on sexual interest, 6.4% provided no answer regard-
ing urinary leakage, and 5.7% had missing data concern-
ing urinary frequency. In comparison, only 0.3% to 1.7%
of the German reference men did not answer these ques-
tions.
Furthermore it has been suggested that missing values are
more common when problems are present (thus, people
are more willing to report the absence of problems) [35].
Under the assumption that missing values indicate a high
level of deterioration, the "true" German values might be
overestimated by our study samples and differences in
QoL ratings between Canada and Germany might be even
more marked than in data presented here. Replacing miss-
ing values with the level indicating the most severe prob-
lem would result in crude PORPUS-P values of 82.6 for
the reference men, 76.2 for RT patients and 79.9 for RP
patients. Replacing missing values with the level indicat-
ing no problem would reveal mean values of 83.3 for the
reference men, 77.5 for RT and 81.2 for RP patients.
Strengths and Limitations
In the present study, we were able to report on three data-
sets from two countries and conduct a cross-national com-
parison of men with PC. One of the strengths is the
inclusion of nearly 1,000 reference men from the general
population, who provided information on prostate spe-
cific and general QoL. Unfortunately, it was not possible
to give a questionnaire on health status to the reference
men, and only 50% of the German PC patients answered
a checklist on co-morbidities, while this information is
available for patients from Canada. The observed age
effect in RP patients may be due to other factors that were
not examined in German patients such as co-morbidity.
In the Canadian study the Charlson co-morbidity score
was computed [14]. Both age and co-morbidity were sig-
nificantly correlated with PORPUS-P scores (for age and
PORPUS-P, r = -0.386, p < 0.001, and for co-morbidity
and PORPUS-P, r = -0.206, p = 0.017). But there was no
significant relationship between age and Charlson score (rBMC Cancer 2009, 9:295 http://www.biomedcentral.com/1471-2407/9/295
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= 0.082, p = 0.34), which might be due to the inhomoge-
neous distribution of Charlson scores in the group. Fur-
thermore, it might be possible that due to differing
exclusion and inclusion criteria for prostate cancer
patients in Germany and Canada both study groups may
be heterogeneous in characteristics that we did not meas-
ure or report here.
More than any other tumour, PC is a neoplasm of the eld-
erly. For example, in Germany, the mean age at diagnosis
is approximately 70 years and more than 90% are aged 60
years or older [2]. The median age of our German cancer
patients was 64 years. In the German studies elderly and
very old patients were not allowed to participate due to
reasons of remembrance abilities and capacity. In the
Canadian study poor cognitive abilities was an exclusion
criterion, and the oldest participant was 79 years. As we
have observed inverse relationships between age and QoL
scoring in all three studies it might be possible that the
reported QoL ratings are too optimistic to be generalized
to all prostate cancer patients (including the elderly and
the very old patients).
Conclusion
The PORPUS-P is a short self-administered questionnaire
which can be easily integrated into research and medical
practice. The German translation of the PORPUS-P
appears to be a feasible tool for assessing prostate-specific
quality of life. Our data show that patients from Canada
and Germany scheduled for RT have lower PORPUS-P
scores than patients scheduled for RP and than reference
men from Germany – with the exception of the oldest age
group included in our studies, in which co-morbidities
might have a greater impact on QoL. Differences in qual-
ity of life between patients scheduled to receive radiother-
apy and radical prostatectomy exist before treatment
starts. Therefore pre-treatment (baseline) quality of life
measures are seriously needed, when effects of different
therapies on quality of life are evaluated.
Although we found a similar response pattern, PC
patients scheduled to receive either RT or RP from Canada
and Germany rated their pre-treatment quality of life on
different levels, which reveals the need for national refer-
ence data.
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